158 related articles for article (PubMed ID: 21844656)
1. Metabolomic analysis reveals novel isoniazid metabolites and hydrazones in human urine.
Li F; Miao Y; Zhang L; Neuenswander SA; Douglas JT; Ma X
Drug Metab Pharmacokinet; 2011; 26(6):569-76. PubMed ID: 21844656
[TBL] [Abstract][Full Text] [Related]
2. Global Urine Metabolomics in Patients Treated with First-Line Tuberculosis Drugs and Identification of a Novel Metabolite of Ethambutol.
Das MK; Arya R; Debnath S; Debnath R; Lodh A; Bishwal SC; Das A; Nanda RK
Antimicrob Agents Chemother; 2016 Apr; 60(4):2257-64. PubMed ID: 26833163
[TBL] [Abstract][Full Text] [Related]
3. Evaluation of the Arkansas method of urine testing for isoniazid in South Africa.
Hanifa Y; Mngadi K; Lewis J; Fielding K; Churchyard G; Grant AD
Int J Tuberc Lung Dis; 2007 Nov; 11(11):1232-6. PubMed ID: 17958987
[TBL] [Abstract][Full Text] [Related]
4. The value of urine testing for verifying adherence to anti-tuberculosis chemotherapy in children and adults in Uganda.
Meissner PE; Musoke P; Okwera A; Bunn JE; Coulter JB
Int J Tuberc Lung Dis; 2002 Oct; 6(10):903-8. PubMed ID: 12365577
[TBL] [Abstract][Full Text] [Related]
5. Isoniazid hepatotoxicity in renal transplant recipients.
Antony SJ; Ynares C; Dummer JS
Clin Transplant; 1997 Feb; 11(1):34-7. PubMed ID: 9067692
[TBL] [Abstract][Full Text] [Related]
6. Use of the urine color test to monitor compliance with isoniazid treatment of latent tuberculosis infection.
Eidlitz-Markus T; Zeharia A; Baum G; Mimouni M; Amir J
Chest; 2003 Mar; 123(3):736-9. PubMed ID: 12628871
[TBL] [Abstract][Full Text] [Related]
7. Point-of-care urine test for assessing adherence to isoniazid treatment for tuberculosis.
Soobratty MR; Whitfield R; Subramaniam K; Grove G; Carver A; O'Donovan GV; Wu HH; Lee OY; Swaminathan R; Cope GF; Milburn HJ
Eur Respir J; 2014 May; 43(5):1519-22. PubMed ID: 24435008
[No Abstract] [Full Text] [Related]
8. A High Dose of Isoniazid Disturbs Endobiotic Homeostasis in Mouse Liver.
Li F; Wang P; Liu K; Tarrago MG; Lu J; Chini EN; Ma X
Drug Metab Dispos; 2016 Nov; 44(11):1742-1751. PubMed ID: 27531952
[TBL] [Abstract][Full Text] [Related]
9. Isoniazid-induced pellagra.
Bilgili SG; Karadag AS; Calka O; Altun F
Cutan Ocul Toxicol; 2011 Dec; 30(4):317-9. PubMed ID: 21517721
[TBL] [Abstract][Full Text] [Related]
10. [Effect of simultaneous administration of 5-bromosalicylhydroxamic acid (T40) and INH on the concentration of free INH in urine of tubercular patients].
Zduńczyk-Pawelek H; Otrzonsek N; Kostrzewska K
Z Tuberk Erkr Thoraxorg; 1965; 124(3):149-52. PubMed ID: 5899137
[No Abstract] [Full Text] [Related]
11. New series of isoniazid hydrazones linked with electron-withdrawing substituents.
Vavříková E; Polanc S; Kočevar M; Košmrlj J; Horváti K; Bosze S; Stolaříková J; Imramovský A; Vinšová J
Eur J Med Chem; 2011 Dec; 46(12):5902-9. PubMed ID: 22018878
[TBL] [Abstract][Full Text] [Related]
12. Isoniazid-related hepatic failure in children: a survey of liver transplantation centers.
Wu SS; Chao CS; Vargas JH; Sharp HL; Martín MG; McDiarmid SV; Sinatra FR; Ament ME
Transplantation; 2007 Jul; 84(2):173-9. PubMed ID: 17667808
[TBL] [Abstract][Full Text] [Related]
13. Monitoring compliance with antituberculous treatment by detection of isoniazid in urine.
Elizaga J; Friedland JS
Lancet; 1997 Oct; 350(9086):1225-6. PubMed ID: 9652571
[No Abstract] [Full Text] [Related]
14. Rifampicin plus pyrazinamide versus isoniazid for treating latent tuberculosis infection: a meta-analysis.
Gao XF; Wang L; Liu GJ; Wen J; Sun X; Xie Y; Li YP
Int J Tuberc Lung Dis; 2006 Oct; 10(10):1080-90. PubMed ID: 17044199
[TBL] [Abstract][Full Text] [Related]
15. Risk of tuberculosis among contacts of isoniazid-resistant and isoniazid-susceptible cases.
Tuberculosis Research Centre, Indian Council of Medical Research (ICMR), Chennai, India
Int J Tuberc Lung Dis; 2011 Jun; 15(6):782-8. PubMed ID: 21575299
[TBL] [Abstract][Full Text] [Related]
16. Prospective randomized control trial of isoniazid chemoprophylaxis during renal replacement therapy.
Vikrant S; Agarwal SK; Gupta S; Bhowmik D; Tiwari SC; Dash SC; Guleria S; Mehta SN
Transpl Infect Dis; 2005; 7(3-4):99-108. PubMed ID: 16390397
[TBL] [Abstract][Full Text] [Related]
17. Isoniazid: metabolic aspects and toxicological correlates.
Preziosi P
Curr Drug Metab; 2007 Dec; 8(8):839-51. PubMed ID: 18220565
[TBL] [Abstract][Full Text] [Related]
18. [Evaluation of compliance with antituberculous chemoprophylaxis among recluse population of the Jaen penitentiary center].
Romero Saldaña M; Vaquero Abellán M; Gallego Rubio R; Aguilera López MD; de Celis Cornejo JM; Barquín García E; Zurita Serrano R
Rev Esp Salud Publica; 1997; 71(4):391-9. PubMed ID: 9490193
[TBL] [Abstract][Full Text] [Related]
19. In vitro and in vivo activities of acylated derivatives of isoniazid against mycobacterium tuberculosis.
Hearn MJ; Cynamon MH
Drug Des Discov; 2003; 18(4):103-8. PubMed ID: 15553921
[TBL] [Abstract][Full Text] [Related]
20. The effect of pyrazinamide and rifampicin on isoniazid metabolism in rats.
De Rosa HJ; Baldan HM; Brunetti IL; Ximenes VF; Machado RG
Biopharm Drug Dispos; 2007 Sep; 28(6):291-6. PubMed ID: 17571294
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
